This article is more than 5 years old. Information may no longer be current.
Ista boosts production of hyaluronidase injection due to shortage
Click Here to Manage Email Alerts
IRVINE, Calif. — Ista Pharmaceuticals is doubling production of Vitrase Ovine 200 USP units/mL after another manufacturer recently announced a shortage of commercial bovine hyaluronidase.
"Ista Pharmaceuticals increased its production to assist the clinical community in maintaining continuous supplies of high quality commercial hyaluronidase," a press release from the company said. "Ista has also initiated direct communications with wholesalers, hospital pharmacists and physicians, as well as increased customer service resources to facilitate continuity of product ordering and availability."
Manufacturer Amphastar Pharmaceuticals previously announced the shortage of its drug Amphadase (hyaluronidase injection USP), according to the release.
Vitrase Ovine (hyaluronidase injection) is a pure, preservative-free ovine hyaluronidase and is indicated as an adjuvant to "increase the absorption and dispersion of other injected drugs," the release said. It is also for hypodermoclysis and an adjunct in subcutaneous urography for enhancing "resorption of radiopaque agents."